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Abstract The heritability of obesity and body weight in
general is high. A small number of conﬁrmed monogenic
forms of obesity—the respective mutations are sufﬁcient
by themselves to cause the condition in food abundant
societies—have been identiﬁed by molecular genetic
studies. The elucidation of these genes, mostly based on
animal and family studies, has led to the identiﬁcation of
important pathways to the disorder and thus to a deeper
understanding of the regulation of body weight. The
identiﬁcation of inborn deﬁciency of the mostly adipocyte-
derived satiety hormone leptin in extremely obese children
from consanguineous families paved the way to the ﬁrst
pharmacological therapy for obesity based on a molecular
genetic ﬁnding. The genetic predisposition to obesity for
most individuals, however, has a polygenic basis. A poly-
genic variant by itself has a small effect on the phenotype;
only in combination with other predisposing variants does
a sizeable phenotypic effect arise. Common variants in the
ﬁrst intron of the ‘fat mass and obesity associated’ gene
(FTO) result in an elevated body mass index (BMI)
equivalent to approximately ?0.4 kg/m
2 per risk allele.
The FTO variants were originally detected in a genome
wide association study (GWAS) pertaining to type 2 dia-
betes mellitus. Large meta-analyses of GWAS have sub-
sequently identiﬁed additional polygenic variants. Up to
December 2009, polygenic variants have been conﬁrmed in
a total of 17 independent genomic regions. Further study of
genetic effects on human body weight regulation should
detect variants that will explain a larger proportion of the
heritability. The development of new strategies for diag-
nosis, treatment and prevention of obesity can be
anticipated.
Keywords Heritability  Genome wide
Introduction
Obesity is a complex disorder that is caused by several
genetic and non-genetic risk factors [1]. The causes of
obesity have been perceived differently over the past
100 years; both biological and psychological explanations
have emerged. In the early part of the twentieth century,
pituitary/hypothalamic dysfunction was assumed to lead to
obesity [2]. From the 1940s through to the 1970s it was
thought that psychological and psychodynamic aspects
played the most prominent role [3, 4]. Prader, Labhart and
Willi described the ﬁrst syndromal form of obesity in 1956
[5]. From the 1970s on, pertinence of (psycho)social fac-
tors has been discussed [6–9]. Milestone twin and adoption
studies at the end of the 1980s and during the early 1990s
provided evidence that genetic factors play a considerable
role in body weight regulation [10–12]. Cloning of the
leptin gene in 1994 [13] led to a rapid expansion of bio-
medical research. Large scale molecular genetic studies
ensued [summarized in: 14]. The successful treatment of
children with leptin deﬁciency [15] with recombinant lep-
tin [16–18] showed for the ﬁrst time that mutations in a
single gene could lead to hyperphagia and obesity. More
recently support has increased for the hypothesis that
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risk factors and a genetic predisposition act in concert
[5, 19, 20]. Recent large scale molecular genetic studies
have substantiated that the genetic predisposition is in
many cases due to the combined net effect of polygenic
variants.
Environmental changes affecting both energy intake and
expenditure are assumed to underlie the recent obesity
epidemic as the gene pool of a population is unlikely to
have changed substantially within the past generation [21].
This is in accordance with the ‘thrifty genotype hypothesis’
[22]. This hypothesis implies that gene variants which
result in an increased energy deposition as fat have accu-
mulated over time to maintain reproductive function as
long as possible and to enhance survival during famines.
Undoubtedly, gene–environment interactions will prove to
play an important role in the aetiology of obesity. Such
interactions could for example be conveyed via changes in
DNA methylation patterns [23].
Recent discussions concern the deﬁnition of obesity or
a subtype(s) of obesity as a psychiatric disorder(s). Res-
olution of this question depends on whether or not obesity
can be viewed as an eating disorder [24]. Undoubtedly,
obesity frequently has a behavioural basis; in addition,
recent biomedical research has indicated that the brain
and in particular the hypothalamus ﬁgure prominently in
the regulation of appetite, body weight and physical
activity. The respective neurotransmitter and neuropeptide
pathways overlap with pathways involved in mood regu-
lation and other psychological traits. Within the context of
this special issue, a focus on the genetics of obesity is
particularly warranted because body weight represents a
readily quantiﬁable phenotype, which is thus amenable to
quantitative genetics. This is in contrast to the categorical
approach frequently taken for psychiatric disorders;
however, due to the fact that many psychiatric disorders
can also be viewed dimensionally, the recent success
pertaining to the elucidation of polygenic variants
involved in weight regulation serves to illustrate this
approach. It may be noted that this success rests on the
analysis of DNA samples of tens of thousands of indi-
viduals [24].
Twin, family and adoption studies
The strongest risk factor for childhood and adolescent
obesity is parental obesity [25]. The risk is especially
elevated if both parents are obese [26]. Some studies have
found a stronger effect of maternal than paternal obesity
[27] which may reﬂect pre- and postnatal environmental
factors and sex-dependent genetic mechanisms. Maternal
weight gain in pregnancy is positively correlated with the
child’s BMI into adulthood [28].
Twin, family and adoption studies have led to the
conclusion that the strong predictive value of parental BMI
mainly stems from genetic rather than environmental fac-
tors [29, 30]. Twin studies, in comparison to family and
adoption studies, have revealed that between 60 and 90%
of the BMI variance within a population can be accounted
for by genetic effects. In single comparatively small twin
studies where the twins were reared apart, the heritability
estimates proved to be similar to those where the twins
were raised together [e.g. 12]. For example, maximum-
likelihood model-ﬁtting analyses and intrapair correlation
coefﬁcients for BMI of identical twins reared apart were
approximately 0.7. This value was comparable to those for
twins reared together. Non-additive genetic variance made
a signiﬁcant contribution to these estimates of heritability
[12]. However, a substantial number of twin pairs reared
apart were not separated immediately after birth, so that
apart from intrauterine inﬂuences, a shared early postnatal
environment could account for inﬂated heritability esti-
mates [29, 31].
Age affects heritability estimates of BMI only to a
minor degree. An exception is the newborn period, for
which a substantially lower heritability (0.4) was calculated
[32]. Intrauterine environment has a strong inﬂuence on
birth weight. It is widely known that, especially for
monozygotic (MZ) twins, other anthropometric measure-
ments, like body height, also correlate less well in infancy
than in childhood. A recent, large scale twin study (lon-
gitudinal sample of more than 3,500 twin pairs) indicated
that the genetic inﬂuence on BMI became progressively
stronger during childhood. Heritability estimates were
shown to increase from 0.48 at age 4 years to 0.78 at age
11 [33]. According to one study [34], the heritability of
BMI is highest during late adolescence (*0.9). However,
one needs to be cautious with the interpretation of twin
studies as they often underestimate shared environmental
effects and tend to overestimate dominant genetic effects.
The pathophysiological and behavioural basis of obesity
is complex and applies to ingestion, absorption, metabo-
lism and energy expenditure. Both macronutrient intake
[35] and activity levels [36] have been shown to be
genetically determined. Restrained eating, drive for thin-
ness and other eating behaviours show heritability esti-
mates in the range of 0.20–0.55 [37]. It appears that even
television viewing may have an, albeit small, heritable
component [38].
Epigenetic considerations
Apart from variation at the DNA level, epigenetic events
are also assumed to contribute to the obesity epidemic
[39, 40]. Modern-day living could affect methylation
patterns of speciﬁc genes which in turn increase the risk
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123of obesity. Fraga et al. [41] observed that during the
early years of life MZ twins are epigenetically indistin-
guishable from each other. However, with increasing age
remarkable differences in their overall content and
genomic distribution of 5-methylcytosine DNA and his-
tone acetylation (with an effect on gene-expression)
become apparent. Such changes induced by the envi-
ronment could have an inﬂuence on individual BMI.
A recent comparison of epigenetic metastability of 6,000
unique genomic regions between matched MZ and
dizygotic (DZ) twins delineated epigenetic differences in
both the MZ and DZ twins. As expected these differ-
ences were much more pronounced in samples of buccal
cells from DZ co-twins. The epigenetic differences
between MZ twins were most pronounced in buccal cells,
but were also observed in gut and blood cells. Whereas
DNA sequence differences could underlie the higher
epigenetic discordance in DZ twins, animal studies and in
silico SNP analyses favour the hypothesis that it is due to
epigenomic differences in the zygotes. Molecular mech-
anisms of heritability may thus not be limited to DNA
sequence differences [42].
In conclusion, family, twin and adoption studies have
provided ample evidence for moderate to high heritability
of BMI. Whereas, current molecular research is focussing
on variation at the DNA level, epigenetic research will
likely add a novel dimension towards the explanation of
intra-individual variance of body weight.
Monogenic obesity
The elucidation of the mutations underlying diverse rodent
mouse models (monogenic and one transgenic) led to the
identiﬁcation of most of the currently known monogenic
forms of obesity in humans [43]. Family studies and in
particular those on consanguineous pedigrees based on
individuals with extreme obesity and in most cases with
additional characteristic phenotypic features, like red hair,
hyperinsulinism and infertility, proved to be highly suc-
cessful in detecting mutations in the homologous human
genes [43, 44]. This work proved fundamental in the
elucidation of the leptinergic–melanocortinergic system.
Put simply, leptin is a mostly adipocyte-derived satiety
hormone that is secreted into the blood. It signals the size
of the fat depot via the nucleus arcuatus in the hypothal-
amus. Increased leptin levels are registered by the leptin
receptor. The signal is than forwarded to the melanocortin
4 receptor (MC4R) in higher order neurons. The endoge-
nous agonist alpha-melanocyte stimulating hormone
(a-MSH; product of the pro-opiomelanocortin gene;
POMC) induces a satiating effect via the MC4R. The brain
derived neurotrophic factor (BDNF) is involved in weight
regulation downstream of the MC4R. Mutations in single
genes of the leptinergic–melanocortinergic pathway have
been shown to have a monogenic effect on the develop-
ment of obesity.
The modes of inheritance of most of the aforementioned
genes are autosomal recessive and autosomal dominant.
The term monogenic obesity requires some speciﬁcation
and discussion: a ‘monogene’ is by common textbook
deﬁnition, a gene with a strong effect on the phenotype
[Mendelian traits or Mendelian (single gene) conditions],
giving rise to a (close to) one-to-one relationship between
genotype and phenotype. A ‘major gene’ is deﬁned as a
gene harbouring, a variant which is associated with a high
lifetime risk for a disease; modiﬁer genes and environ-
mental factors additionally play a role in the aetiology of
the respective diseases [45–47].
The distinction between monogenic obesity and obesity
due to a major gene effect may appear semantic. However,
because BMI is a quantitative trait with obesity repre-
senting the right tail of the distribution, attempts to address
this distinction are warranted.
Consider mutations in the MC4R, which have been
reported to result in monogenic obesity [e.g. 48, 49]. In
Mc4r knock-out mice the heterozygous animals have a
body weight in between the wild-type and homozygous
knockout mice [50]; body weight distributions of mice with
heterozygous and wild-type genotypes overlap substan-
tially, particularly in male rodents. The obese phenotype in
the knock-out mice led to mutation screens of the human
MC4R. The initial detections of human mutation carriers
were all based on small pedigrees [51–53]. Subsequent
studies revealed that mutation carriers are not necessarily
obese [e.g. 54, 55]. An epidemiological study based on
approximately 4,000 individuals assessed within the
framework of a population-based study revealed that none
of the 6 individuals with functionally relevant MC4R
mutations were obese [56]. Finally, in an attempt to adjust
for familial background genetic and environmental factors
Dempﬂe et al. [57] analysed current BMI of mutation and
wild-type carriers in pedigrees based on index patients with
MC4R mutations. The differences amounted to 4.5 and
9.5 kg/m
2 in males and females, respectively [57].
Accordingly, instead of using the term monogenic obesity,
we consider it more appropriate to think of MC4R muta-
tions as resulting in strong effect sizes conveying a high
lifetime risk for obesity. The effect sizes of these mutations
are lower than those of the leptin or leptin receptor gene
mutations [43]. In contrast, the few individuals who were
found to be homozygous or compound heterozygous for
functionally relevant MC4R mutations were all extremely
obese [55, 58].
Over the past 10–15 years mutations in several genes
such as those coding for leptin (LEP [15, 59]), leptin
receptor (LEPR [60]), prohormone convertase 1 (PC1
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123[61, 62]) and pro-opiomelanocortin (POMC [63, 64]) have
been shown to lead to autosomal recessive forms of obesity
[14]. These mutations are all rare and lead, apart from
extreme obesity with an early onset, to additional pheno-
typical manifestations, including red hair (POMC), reduced
or impaired fertility (PC1, leptin and LEPR), adrenal
insufﬁciency (POMC), and impaired immunity (LEP)
[16, 43, 65]. The pleiotropic effects warrant the consider-
ation that these recessive disorders are classiﬁed as syn-
dromal forms of obesity—similar to the Bardet–Biedl,
Prader–Willi and other genetic syndromes associated with
obesity [43, 66]. The pleiotropic Bardet–Biedl syndrome,
of which obesity is one of the main clinical features, has
been shown to have an oligogenic basis [14, 19, 43]. It was
expected that the syndromic forms of obesity could help to
unravel novel genes relevant for idiopathic obesity. How-
ever, although the genes for several of the syndromic forms
have been detected, the relevance of these genes for gen-
eral obesity is still unclear [14].
Both young [16, 17] and adult [67] individuals with
inborn leptin deﬁciency have been treated successfully
with recombinant leptin; weight loss (primarily fat mass)
was shown to be substantial. Farooqi et al. [16, 18, 68, 69]
described the rapidly altered eating behaviour upon initi-
ation of treatment with recombinant leptin; food ingestion
ceased to be the major focus of daily (and nightly)
activity of the thus treated children [16, 18, 68, 69]. This
is the ﬁrst and until now only genetic form of human
obesity that is amenable to successful pharmacological
treatment.
The MC4R has been shown to comprise mutations
entailing a substantially elevated body weight (see above)
and two polymorphisms, which both have a small protec-
tive effect for the development of obesity (see below; e.g.
[70, 71]. Currently, over 130 functionally relevant muta-
tions have been detected in the human MC4R gene [72].
About 2–6% of extremely obese children and adolescents
harbour such mutations. Among obese adults the preva-
lence is seemingly lower (1–2%). Approximately 0.5% of
the normal weight population also harbour such mutations
[56]. In vitro analyses have shown that most of these
mutations lead to either total or partial loss of function
[73, 74]. Thus, the endogenous agonist alpha-melanocyte
stimulating hormone (a-MSH) is not able to induce its
satiating effect to a full extent. Children with MC4R
mutations have been shown to eat larger meals [58].
A negative effect of the mutations on energy expenditure
also appears likely [75].
Phenotypical effects of MC4R mutations other than
obesity have been shown to encompass hyperinsulinemia,
elevated growth rate and higher bone density [58]. An
initial report that MC4R mutations induce binge eating was
not conﬁrmed in subsequent investigations [19, 76–79].
Statistical approaches
To detect new obesity gene variants, different approaches
have been employed [80]:
(1) Association studies
Several candidate genes have been analysed because of
a priori biological, physiological or pharmacological evi-
dence of their involvement in central or peripheral path-
ways controlling energy intake or expenditure [14]. A large
number of conventional association studies involving obese
cases and normal weight and/or lean controls, or less fre-
quently studies of families have been performed [14];
meta-analyses have been reported for only a small number
of such identiﬁed genetic variants. Unfortunately, classical
candidate gene studies have proven largely unsuccessful in
reliably detecting novel genetic variants relevant for
obesity. Identiﬁcation of a candidate gene can also rely on
its location within a linkage region or a region identiﬁed
via genome wide association studies (GWAS). In GWAS
up to 2,000,000 genetic variants can currently be analysed
for association with a given phenotype. This approach has
been extremely successful for various phenotypes [81]. As
the effect sizes are usually small, large groups need to be
screened. Because in the pre-GWAS era sample sizes
rarely exceeded 1,000 cases and 1,000 controls and in light
of the small effect sizes of polygenic variants detected
recently in GWAS, it must be concluded that most classical
candidate gene studies were underpowered. It remains to be
seen to what extent such genetic variants (and subsequently
candidate genes) will be picked up in future large scale
GWAS meta-analyses.
(2) Genome wide approaches
(a) Genome wide linkage studies aim to identify chro-
mosomal regions harbouring one or more genes relevant
for a respective phenotype by making use of linkage data.
Those regions underlying linkage peaks are narrowed down
by ﬁne mapping, so that candidate gene analyses can be
pursued. Although more than 40 microsatellite-based
genome wide linkage scans have been performed and sin-
gle candidate genes have been detected, none of the results
have been validated unequivocally [82]. This supports the
contention that the effect sizes of genes inﬂuencing adi-
posity are small and/or that substantial heterogeneity exists
[83].
(b) GWAS provide a better design to identify common
variants with low to moderate penetrance which are rele-
vant as risk factors for the trait of interest. Within a short
time span, GWAS have proven to be very successful for the
detection of polygenic variants. The production of high
density SNP-chips has made GWAS feasible, which only
recently have led to the identiﬁcation of a number of
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revolutionizing the molecular genetic analyses of complex
disorders [81]. Stringent efforts to conﬁrm (or reject) an
original ﬁnding are absolutely crucial; due to the low effect
sizes and possible gene–environment interactions it is to be
expected that not every study will be able to conﬁrm a true
positive ﬁnding; meta-analyses are required. GWAS per-
formed for obesity or body mass index (see Table 1) have
already documented that this approach is extremely pow-
erful to detect genetic variants relevant for the analysed
phenotype(s). Currently known polygenic variants have a
mean effect on BMI of approximately 0.03–0.5 kg/m
2;i t
appears reasonable that these effect sizes represent the
upper limit of such common variants [84–86]. Independent
gene variants with small but replicable effects on body
weight have been identiﬁed unambiguously in 17 gene
regions so far [86].
Polygenic obesity
Some traits can be due to the simultaneous presence of
DNA variation in multiple genes. Any of a group of alleles
at distinct gene loci that collectively control the inheritance
of a quantitative phenotype or modify the expression of a
qualitative character are termed ‘polygenic’ variants. It is
generally assumed that for quantitative traits, each allele
has a small effect and the allelic effects can be additive or
non-additive. Potentially, many such polygenic variants
play a role in body weight regulation. It is estimated that
the total number of genes with a small effect most likely
exceeds 100. The lower limit of effect sizes will most
likely be well below 100 g. If an individual harbours many
polygenic variants that increase body weight, obesity can
ensue. Any single variant will have a higher frequency in
obese than in normal weight and lean individuals [83].
A polygenic basis of obesity implies that the speciﬁc set of
polygenic variants relevant for obesity in one individual is
unlikely to be the same in another obese subject.
Melanocortin-4 receptor gene (MC4R)
The coding region of the MC4R harbours, in addition to the
‘obesity mutations’ mentioned above, two polygenic vari-
ants for weight regulation: the minor alleles of the poly-
morphisms coding for isoleucine instead of valine at amino
acid position 103 (103I) and for leucine instead of isoleu-
cine at position 251 (251L) of the receptor protein are
negatively associated with obesity [70, 71, 87–89], the
mean BMI of such carriers is slightly reduced in comparison
to homozygous carriers of the major allele. Heterozygosity
for the I103 variant was found in 2–9% of subjects from
different populations [70]. A family-based association test
(TDT) in 520 trios ascertained via a young obese offspring
originally revealed under-transmission of the allele coding
for the I103 variant. A ﬁrst meta-analysis comprising 7,713
cases and controls substantiated the evidence for a negative
association of the I103 variant with obesity (odds ratio:
0.69). An effect estimate of -0.48 kg/m
2 was calculated for
I103 carriers [70]. This negative association of I103 with
obesity was subsequently conﬁrmed in a single large epi-
demiological studygroup comprising 7,937 individuals [87]
and two further meta-analyses encompassing a total of
55,195 individuals [88, 89]. The MC4 receptor variant
harbouring I103 revealed a modest (twofold) decrease in
antagonist hAGRP(87–132) potency [90], which is consis-
tent with the obesity protective effect conferred by this
variant.
The inﬂuence of the second non-synonymous coding
polymorphism (I251L; rs52820871) on body weight was
detected in 16,797 individuals of European origin from
nine independent case–control, population-based studies
and family cohorts. A consistent negative association of the
L251 variant (minor allele frequency in cases and controls
ranged from 0.41 to 1.21%) with both childhood and adult
extreme obesity (odds ratio ranging from 0.25 to 0.76) was
detected in eight of the nine studies; the variant was also
associated with reduced BMI in population-based samples.
A meta-analysis supported the evidence of the obesity
protective effect of MC4R L251 (OR = 0.52) [71].
Most recently, SNP rs17782313 188 kb downstream of
MC4R was detected via a large scaled GWAS [85], thus
further substantiating the important contribution of genetic
variation at the MC4R locus to inter-individual differences
in BMI. For the ﬁrst step, GWAS data from seven studies
including 16,876 European individuals had been ana-
lyzed jointly. The second strongest association signal
(p = 2.9 9 10
-6,after FTO,see below) was atrs17782313.
Due to its position downstream of the MC4R its inﬂuence on
weight regulation is likely to be mediated through effects on
MC4R expression. The ﬁnding was conﬁrmed in 60,352
adults and 5,988 children and 660 German nuclear families
encompassingoneormoreobeseoffspringandbothparents.
Each copy of the rs17782313 C-allele was associated with a
mean difference in BMI of approximately ?0.22 kg/m
2
(?760 g). One copy of the C-allele resulted in an 8 and 12%
increased odds ratio for overweight and obesity, respec-
tively; no signiﬁcant gender differences were detected. The
effect on weight was disproportionately due to fat mass.
The effect of the C-allele was not detectable in children
at birth and up to 42 months of age in the Avon Longitu-
dinal Study of Children and Parents (almost 6,000 chil-
dren) [85]. However, the effect size of one C-allele in
children aged 7–11 was twice the amount observed in
adults. Interestingly, in adults—but not in children—one
copy of the C-allele also resulted in a higher mean height
(0.21 cm) implying that this SNP [or the functionally
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123Table 1 Genetic variants with a polygenic effect on body weight in humans
SNP Chr Position Nearest gene Sample size
in the
original
publication
a
Frequency
of the risk
allele
(risk allele)
Effect on BMI
in the original
publication
References
rs2815752 1 72,524,461 NEGR1 32,387 62% (A) ?0.10 kg/m
2 per A allele
b [92]
rs2568958 1 72,537,704 NEGR1 25,344 58% (A) ?0.43 kg/m
2 for AA genotype
c [84]
rs10913469 1 176,180,142 SEC16B, RASAL2 25,344 20% (C) ?0.50 kg/m
2 for CC genotype
c [84]
rs6548238 2 624,905 TMEM18 32,387 84% (C) ?0.26 kg/m
2 per C allele
b [92]
rs7561317 2 634,953 TMEM18 25,344 84% (G) ?0.70 kg/m
2 for GG genotype
c [84]
rs7566605 2 118,552,495 INSIG2 9,881 37% (C) ?1.00 kg/m
2 for CC genotype [121]
rs7647305 3 187,316,984 SFRS10, ETV5, DGKG 25,344 77% (C) ?0.54 kg/m
2 for CC genotype
c [84]
rs10938397 4 45,023,455 GNPDA2 32,387 48% (G) ?0.19 kg/m
2 per G allele
b [92]
rs4712652 6 22,186,593 PRL 2,796 41% (A) ?0.031 kg/m
2 per A allele in
children
d
[126]
rs10508503 10 16,339,956 PTER 2,796 8.5% (C) ?0.144 kg/m
2 per C allele in
children
d
[126]
rs6265 (V66M) 11 27,636,492 BDNF 25,344 85% (G) ?0.67 kg/m
2 for GG genotype
c [84]
rs10838738 11 47,619,625 MTCH2 32,387 34% (G) ?0.07 kg/m
2 per G allele
b [92]
rs7138803 12 48,533,735 BCDIN3D, FAIM2 25,344 37% (A) ?0.54 kg/m
2 for AA genotype
c [84]
rs7498665 16 28,790,742 SH2B1 32,387 41% (G) ?0.15 kg/m
2 per G allele
b [92]
rs7498665 16 28,790,742 SH2B1, ATP2A1 25,344 44% (G) ?0.45 kg/m
2 for GG genotype
c [84]
rs8050136 16 52,373,776 FTO 25,344 41% (A) ?1.07 kg/m
2 for AA genotype
c [84]
rs9939609 16 52,378,028 FTO 38,759 40% (A) ?0.40 kg/m
2 per A allele [95]
rs9939609 16 52,378,028 FTO 32,387 41% (A) ?0.33 kg/m
2 per A allele
b [92]
rs1421085 16 52,358,455 FTO 2,796 40% (C) ?0.112 kg/m
2 per C allele
d [126]
rs1424233 16 78,240,251 MAF 2,796 43% (A) ?0.091 kg/m
2 per A allele in
children
d
[126]
rs1805081 18 19,394,429 NPC1 2,796 44% (A) -0.087 kg/m
2 per A allele in
children
d
[126]
rs17782313 18 56,002,077 MC4R 16,876 24% (C) ?0.22 kg/m
2 per C allele [85]
rs17782313 18 56,002,077 MC4R 32,387 22% (C) ?0.22 kg/m
2 per C allele
b [92]
rs17782313 18 56,002,077 MC4R 2,796 17,5% (C) ?0.097 kg/m
2 per C allele
d [126]
rs12970134 18 56,035,730 MC4R 25,344 30% (A) ?0.36 kg/m
2 for AA genotype
c [82]
rs52820871 (I251L) 18 56,189,806 MC4R 16,797 0.75% (251L) -0.35 SD of their BMI Z-score
per 251L allele
[71]
rs2229616 (V103I) 18 56,190,256 MC4R 7,713 2% (103I) -0.48 kg/m
2 per 103I allele [70]
rs29941 19 39,001,372 CHST8, KCTD15 25,344 70% (C) ?0.46 kg/m
2 for CC genotype
c [84]
rs11084753 19 39,013,977 KCTD15 32,387 67% (G) ?0.06 kg/m
2 per G allele
b [92]
a Either in the GWAS or the initial sample
b Reported in the population-based cohorts EPIC, FINRISK97, BPPP and METSIM (N = 18,812; [92])
c Reported for the Islandic sample (N = 25,344; [84])
d reported for children from the Northern Finland Birth Cohort (N = 5,291; [126]), adapted from [86]
NEGR1: neuronal growth factor regulator 1; SEC16B; cerevisiae, homolog of, B; RASAL2: RAS protein activator like 2; TMEM18: trans-
membrane protein 18, INSIG2: insulin induced gene 2, SFRS10: splicing factor, arginine/serine-rich, 10; ETV5: ets variant 5; DGKG diacyl-
glycerol kinase, gamma, 90kD, GNPDA2: glucosamine-6-phosphate deaminase 2; PRL: prolactin; PTER: phosphotriesterase related; BDNF:
brain derived neurotrophic factor; MTCH2: mitochondrial carrier homolog 2 (C. elegans); BCDIN3D: BCDIN3 domain containing; FAIM2: Fas
apoptotic inhibitory molecule 2; SH2B1: SH2B adaptor protein 1; ATP2A1: ATPase, Ca?? transporting, cardiac muscle, fast twitch 1; FTO: fat
mass and obesity associated; MAF: v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog (avian); NPC1: Niemann-Pick disease, type C1;
MC4R: melanocortin 4 receptor; CHST8: carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8; KCTD15: potassium channel tetr-
amerisation domain containing 15
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123relevant SNP(s) in linkage disequilibrium] also affects
overall adult size. This ﬁnding has been replicated [91–94].
Fat mass and obesity associated gene (FTO)
FTO was among the genes highlighted in GWAS for type 2
diabetes mellitus (T2DM) [95, 96]. By adjustment for BMI
it was [95] found that the association to T2DM was actu-
ally due to the higher BMI of diabetic cases in comparison
to non-diabetic controls. Conﬁrmation of this effect on
body weight was obtained in 13 cohorts with a total of
38,759 individuals within a meta-analysis showing that the
A-allele of the variant rs9939609 (intron 1) was associated
with a 31% increased risk to develop obesity. Among the
adults 16% were homozygous for this risk-allele. When
compared with individuals harbouring no copy of the risk-
allele, they had a 1.67-fold increased odds ratio for obesity;
mean body weights of these two groups differed by
approximately 3 kg.
The association of SNPs in intron 1 of FTO has been
conﬁrmed in all sufﬁciently sized subsequent replication
studies [e.g. 97–99]. The ﬁrst GWAS speciﬁcally designed
with a primary focus on obesity was performed in 487
extremely obese German children and adolescents and 442
lean controls [99]. Six SNPs in FTO showed the strongest
evidence for association with obesity, one of which
remained signiﬁcant after correcting for multiple testing.
The odds ratios for obesity for heterozygosity and homo-
zygosity for the risk allele were 1.67 and 2.76, respectively.
A longitudinal study of children aged 7 months (n = 640)
at baseline to 15 years, showed that the FTO effect became
evident from age 7 years on. In this study, FTO variants
were not associated with energy intake or physical activity
[100]. However, association was found between FTO risk
variants and increased energy intake in adults [101–103]
and decreased satiety [103], but not for energy expenditure
[101, 102] or physical activity [100, 104].
Among 190 children and adolescents, those with at least
one FTO risk allele reported episodes of loss of control
over eating more frequently than individuals homozygous
for the non-risk allele. Additionally, those children with
risk alleles selected foods with a higher fat content at a
buffet meal [105]. A large scale study (n = 4,839 popu-
lation-based adults) revealed that low physical activity and
high-fat diets might be especially obesity promoting in
FTO risk allele carriers [106]. FTO risk alleles did not
predict weight loss in obese children undergoing a 1-year
intervention or their baseline fasting levels of blood glu-
cose, triglycerides and cholesterol [107]. However, within
the 280 participants the homozygous carriers of risk vari-
ants of both FTO and INSIG2 (insulin induced gene 2; see
below) showed the lowest degree of overweight reduction
[108]. As some of the studies mentioned above were rather
small scale (n\500 e.g. [100, 101, 105, 107–109], additional
conﬁrmatory studies are warranted.
The strong association of genetic variation within FTO
to obesity has led to a series of functional studies: FTO
expression in skeletal muscle and adipose tissue in humans
is seemingly not inﬂuenced by this variation [110]. An age-
dependent decline in FTO expression was found to concur
with peripheral defects of glucose and fat metabolism
[112]. One of the obesity SNPs in intron 1 was associated
with a reduced insulin effect on beta activity measured by
magneto encephalography, which implicates a lower
cerebro cortical response to insulin. This might be a
mechanism by which variation in FTO contributes to the
pathogenesis of obesity [111]. Wa ˚hle ´n et al. [112] sug-
gested a role of the FTO in fat cell lipolysis, thus providing
a functional link to body weight regulation.
Human FTO is apparently a member of the non-heme
dioxygenase (Fe(II)- and 2-oxoglutarate-dependent dioxy-
genases) superfamily [113, 114]. Amino acid conservation
patterns support this hypothesis [114]. FTO belongs to the
AlkB-related protein family [Gerken]. Recombinant mur-
ine Fto catalyzes demethylation of 3-methylthymine and
3-methyluracil residues in single-stranded DNA and RNA
in vitro, although the efﬁciency is poor. Consistent with a
potential role in nucleic acid demethylation, Fto localizes
to the nucleus in transfected cells. Initially, it was criticised
that 3-methylthymine and 3-methyluracil residues were
analysed although they are rather uncommon in humans.
Later it was shown, that Fto was also working, although
less actively, on the more common forms of methylated
DNA base damage (1-methyladenine and 3-metylcytosine)
[112, 115]. Fto messenger RNA (mRNA) is most abundant
(in comparison to all analysed tissues) in mouse brain and
in particular in hypothalamic nuclei governing energy
balance. In the arcuate nucleus, Fto mRNA levels have
been found to be regulated by feeding and fasting [113].
FTO is ubiquitously expressed in human embryonic and
adult tissues [116, 117].
Recently, it was shown that the loss of Fto in mice leads
to postnatal growth retardation and a signiﬁcant reduction
in adipose tissue and lean body mass [118]. The leanness of
Fto deﬁcient mice (Fto
-/
-) develops as a consequence of
increased energy expenditure and systemic sympathetic
activation, despite decreased spontaneous locomotor
activity and relative hyperphagia. The heterozygous Fto
?/
-
mice have a reduced Fto expression leading to a signiﬁ-
cantly reduced weight gain after 12 weeks compared to
wild-type mice. Thus, the animal model for the ﬁrst time
demonstrated that Fto is functionally involved in energy
homeostasis by the control of energy expenditure [118].
A dominant point mutation induced by ENU (N-ethyl-N-
nitrosourea) mutagenesis in the murine Fto gene also
resulted in reduced fat mass and increased energy
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unaltered. High-fat diet led to increased lean mass and
reduced fat mass in comparison to controls [119]. Based on
these ﬁndings it appears that the human FTO risk variants
in intron 1 are associated with an increased expression of
FTO.
FTO is essential for normal development of the central
nervous and cardiovascular systems in humans as shown by
individuals with loss of function mutations in FTO: Boissel
et al. [117] ascertained a large Palestinian Arab consan-
guineous multiplex family in which nine affected individ-
uals presented with a novel polymalformation syndrome
including postnatal growth retardation, microcephaly,
severe psychomotor delay, functional brain deﬁcits and
characteristic facial dysmorphic features. Some patients
also presented with structural brain malformations, cardiac
defects, genital anomalies and cleft palate. Intercurrent
infection or unidentiﬁed causes led to early lethality which
occurred at 1–30 months of age. By linkage and sequence
analyses a causative non-synonymous FTO mutation
(R316Q) was detected homozygously in affected individ-
uals. The mutation is located in an evolutionarily con-
served region of FTO and leads to an inactivation of the
enzymatic activity. Unfortunately, anthropometric data
were not available for the unaffected family members;
none of the heterozygous parents were clinically obese.
Heterozygous carriers of loss of function mutations in FTO
might be relatively resistant to become obese [117].
Recently, a large scale mutation screen in the coding
region of FTO in 1,433 severely obese and 1,433 lean
humans revealed novel mutations [120]. Functional in vitro
studies showed that two of these mutations led to a reduced
FTO function. Although the animal models implied that
FTO deﬁciency should be related to leanness [118, 119] the
two mutations were detected in both lean and obese indi-
viduals [120].
Insulin induced gene 2 (INSIG2)
The ﬁrst GWAS for body weight (100k, Affymetrix) was
conducted in 694 individuals from 288 families of the
Framingham Heart Study [121]. In both children and
adults, homozygosity for the minor allele of a common
SNP (rs7566605) in the vicinity of INSIG2 was found to be
associated with obesity. The initial ﬁnding was conﬁrmed
in four of ﬁve separate samples comprised of individuals of
Western European ancestry and African-Americans.
Approximately 10% of the individuals harboured the
obesity prone CC genotype, which conferred an average
increase in BMI of approximately one BMI unit. A meta-
analysis comprising all case–control samples showed that
under a recessive model, the CC genotype was signiﬁcantly
associated with obesity (OR = 1.22) [121].
Several attempts to replicate the INSIG2 ﬁnding have
been undertaken. Both conﬁrmations as well as negative
ﬁndings have been reported [122–125]. INSIG2 was not
detected in any of the (joint) GWAS for obesity or BMI or
in case–control studies [84, 86, 126]. A recent meta-
analysis comprised data on a total of 74,345 individuals.
Evidence for an overall association of rs7566605 with
obesity was not detected. However, the data suggested an
association with extreme degrees of obesity [127].
Other loci detected in genome wide association studies
Novel loci were identiﬁed by genome wide association
studies in large study groups and via meta-analyses. Apart
from the ﬁrst large-scale meta-analysis mentioned above
[85], three more recent GWAS reported novel obesity
genes with small effects on human body weight [84, 92,
126]. A total of more than 150,000 individuals was ana-
lysed (Table 1).
A GWAS that was mainly based on individuals of the
Icelandic population [84] resulted in a total of 29 variants
in 11 chromosomal regions that reached genome wide
signiﬁcance, amongst them, variants located in seven new
loci for obesity. Furthermore, FTO and MC4R were
reconﬁrmed as well as the two obesity candidate genes
brain derived neurotrophic factor gene (BDNF) and SH2B
adaptor protein 1 gene (SH2B1)[ 84]. Four of the novel
seven loci were not detected in the other two recent GWAS
(see below and Table 1). Parallel to the Icelandic study
[84], the meta-analysis of 15 GWAS for BMI (n = 32,387)
was extended by the ‘Genetic Investigation of ANthropo-
metric Traits’ consortium (GIANT) [92]; the study was
also based on the GWAS data analysed by Loos et al. [85].
The best signals were now followed-up in 14 additional
cohorts (n = 59,082). Again, strong conﬁrmation was
detected for FTO and MC4R. Additionally, six novel loci
were identiﬁed (see Table 1).
Interestingly, for the ﬁrst time a copy number variation
(CNV) was described as potentially relevant for obesity
[128] CNVs are by deﬁnition repeats of a size of 1 kb and
more [129]. It is assumed that they might be involved in the
regulation of neighbouring genes. The frequent ‘obesity-
CNV’ (a 45-kb deletion) is located in a region near the
neuronal growth regulator 1 gene (NEGR1). Further studies
are required to unravel the underlying molecular
mechanisms.
The newly detected variants lead to an increase of
0.06–0.33 kg/m
2 BMI units per allele. In adults with a
height of 170 cm this corresponds to 173–954 g per allele.
According to the recent GIANT study [92], the six newly
discovered loci account for 0.40% and in combination with
FTO and MC4R for a total of 0.84% of the BMI variance.
The assessment of the combined impact of these loci on
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predisposing alleles across the eight loci were on average
1.46 BMI units (equivalent to 3.7–4.7 kg for an adult of
average height) heavier than those individuals with less
than three of these alleles [92]; the effects proved to be
additive.
The third recent GWAS [126] comprising roughly 3,000
Europeans and a large conﬁrmatory study group revealed,
in addition to FTO and MC4R, signiﬁcant association with
obesity for three new risk loci (see Table 1). The poly-
morphism coding for 103I of the MC4R [e.g. 17] was also
reconﬁrmed.
Conclusions and perspectives
Animal models and family studies led to the identiﬁcation
of rare monogenic forms of human obesity. The more
common MC4R mutations in our opinion are more
consistent with a ‘major gene effect’, as the near one-
to-one relationship between genotype and phenotype is not
evident among carriers of the risk allele. Instead, these
individuals have a substantially increased risk of develop-
ing obesity. This initial work led to the discovery of the
leptinergic–melanocortinergic pathway, which ﬁgures
prominently in body weight regulation. Genome wide
linkage and classical candidate gene studies were largely
unsuccessful to identify obesity genes; these studies were
underpowered. The emergence of GWAS has recently
revolutionized the ﬁeld in terms of detection of variants
with small effect sizes.
Seventeen solidly conﬁrmed polygenic variants for body
weight regulation have been reported as of October 2009. It
is obvious that more polygenic variants await detection;
undoubtedlylargescaleGWASwillprovepowerfulfortheir
elucidation. It will be interesting to determine if the effect
sizesofthecurrentlyknownpolygenicvariantsrepresentthe
upper limit. Effect sizes of many as yet undetected variants
could well be in the range of\50 g only. The detection of
such variants will require meta-analyses based on hundreds
of thousands of individuals. For those currently known
polygenes, studies on gene–gene interactions can be
undertaken. Finally, gene–environment interactions also
become amenable to statistical analyses.
If a large number of genetic variants are detected in the
future, prediction will potentially become feasible. In most
cases, a straightforward but detailed family history would
currently provide much more predictive power. However,
the analysis of a family history cannot indicate the
involvement of speciﬁc genetic or biochemical mecha-
nisms. Hence, genetic tests could provide much more
detailed data pertaining to the pathways predisposing to
obesity within the analysed family.
As obviously only a small fraction of the variance of
BMI can currently be explained by variation at the DNA
level, one might speculate about the molecular mechanisms
underlying the large proportion of as yet unexplained
variance. As already pointed out, the effect sizes of gene
variants might be very small. Another explanation is that
obesity frequently results from infrequent variants with
larger effect sizes; substantial heterogeneity might preclude
their detection. Additionally, one has to bear in mind that
the highly dense SNP-chips only cover a major part but not
all the variation in the human genome. Furthermore, hap-
lotypes instead of SNPs might prove more successful for
unraveling novel genes for obesity. Complex gene–gene
and gene–environment interactions may also contribute to
the currently low explained BMI variance. If at any given
locus relevant for body weight regulation, some SNPs lead
to an elevated expression, others to a reduced expression,
such loci might also escape detection using current tech-
nology. Finally the role played by CNVs in obesity requires
scrutiny and the inﬂuence of epigenetic factors on the
development of obesity merits close attention.
The future will show to what extent BMI variance at the
population level can be explained at the molecular level
[130]; this will have a profound impact as to the feasibility
of diagnostic kits to detect obesity genes. The current
obesity intervention programs are not very efﬁcient, so that
novel approaches for treatment have to be developed. Gene
products of every detected polygene can be considered as a
potential drug target for the treatment of obesity and
associated disorders.
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